CSIG-27. DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA

BACKGROUND: Benefit from temozolomide chemotherapy in glioblastoma is essentially limited to patients with tumors that exhibit O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation. Recent retrospective clinical analyses indicate that the impact of the MGMT status on chemosensitivity...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Principais autores: Silginer, Manuela, Papachristodolou, Alexandros, Hentschel, Bettina, Gramatzki, Dorothee, Felsberg, Jörg, Löffler, Markus, Schackert, Gabriele, Westphal, Manfred, Tonn, Jörg-Christian, von Deimling, Andreas, Pietsch, Torsten, Reifenberger, Guido, Roth, Patrick, Weller, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216676/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.193
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados